Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Treatment entities : Gilead sciences, inc. save search
Citius Pharmaceuticals Announces Addition of City of Hope to UMN's Phase 1 Trial of LYMPHIR in Combination with CAR-T for the Treatment of B-Cell Lymphoma
Published: 2024-04-11 (Crawled : 20:00) - biospace.com/
FNCTF | News | $11.16 -20.84% 130
|
Communications
|
| O: -100.0%
H: NaN%
C: Infinity%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.5%
H: 0.83%
C: 0.28%
CTXR | $0.7199 -6.18% -6.58% 880K
|
Health Technology
|
| O: 2.33%
H: 2.28%
C: -4.23%
hope treatment pharmaceuticals city for car-t trial
Global Neutropenia Market Poised to Reach USD 5.86 Billion by 2028, Amid Rising Cancer Incidence and Advancements in Treatment Options
Published: 2024-03-18 (Crawled : 00:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.02%
H: 0.0%
C: 0.0%
BAX | $40.93 -0.22% 0.0% 2.2M
|
Health Technology
|
| O: 0.02%
H: 1.03%
C: 0.96%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: -1.51%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.11%
H: 0.59%
C: 0.1%
BIIB | $201.91 4.52% 4.32% 3.3M
|
Health Technology
|
| O: -0.48%
H: 0.31%
C: 0.13%
reach cancer treatment global market
Global Pseudomonas Aeruginosa Infection Treatment Market Report 2024-2034: Rising Antibiotic Resistance Drives Demand for Pseudomonas Aeruginosa Infection Treatments
Published: 2024-01-17 (Crawled : 02:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -0.56%
H: 0.0%
C: 0.0%
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -1.83%
H: 0.0%
C: 0.0%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 0.49%
H: 0.18%
C: 0.04%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -1.02%
H: 0.0%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.08%
H: 0.1%
C: -0.18%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 0.12%
H: 0.77%
C: 0.27%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 0.45%
H: 0.06%
C: -0.5%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.19%
H: 0.87%
C: 0.76%
report infection treatment global market
Kadcyla Leads the Global Antibody Drug Conjugates Market with Extensive Use in Breast Cancer Treatment
Published: 2023-11-01 (Crawled : 18:00) - prnewswire.com
ALPMY | News | $9.49 -1.11% 480K
|
Manufacturing
|
| O: -1.46%
H: 3.67%
C: 3.26%
ZYME | $8.555 -0.06% -0.06% 590K
|
Health Technology
|
| O: 1.14%
H: 0.42%
C: -0.7%
TAK | News | $13.23 -1.12% 0.0% 920K
|
Health Technology
|
| O: 1.03%
H: 0.73%
C: 0.58%
ADCT | $4.78 -3.82% 0.0% 280K
|
Health Technology
|
| O: -0.16%
H: 6.42%
C: 4.49%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -0.86%
H: 0.0%
C: 0.0%
STRO | $3.47 -6.72% -7.2% 540K
|
Health Technology
|
| O: 0.39%
H: 3.86%
C: 3.86%
IMGN | News | $31.23 0.03% 49M
|
Health Technology
|
| O: 5.09%
H: 5.48%
C: -1.27%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.47%
H: 1.88%
C: 1.78%
EXEL | $23.7 1.76% 1.73% 1.5M
|
Health Technology
|
| O: -2.62%
H: 1.17%
C: -1.66%
drug antibody breast cancer treatment global market
Real-World Evidence Reinforces Biktarvy® as a Long-Term Treatment Option With a High Barrier to Resistance for People With HIV and a Range of Comorbidities
Published: 2023-10-19 (Crawled : 10:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.75%
H: 1.01%
C: -0.8%
biktarvy treatment hiv
Kite’s Car T-cell Therapy Yescarta® Demonstrates High Response Rate and Durable Remission in ALYCANTE Study as Initial Treatment for Transplant Ineligible Patients With Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-09-18 (Crawled : 09:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.25%
H: 0.38%
C: -0.32%
yescarta t-cell treatment response therapy study
FDA Approves Veklury® (Remdesivir) for COVID-19 Treatment in Patients With Severe Renal Impairment, Including Those on Dialysis
Published: 2023-07-14 (Crawled : 14:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.13%
H: 1.34%
C: 0.76%
covid-19 veklury fda renal treatment dialysis
Gilead Partners with CHAI and Penta to Improve Treatment and Adherence Rates Among Children with HIV in Low and Middle Income Countries
Published: 2023-07-13 (Crawled : 11:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.42%
H: 0.77%
C: 0.01%
children treatment hiv
Kite’s Yescarta® CAR T-cell Therapy Demonstrates Significantly Longer Overall Survival Versus Standard of Care as Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-06-05 (Crawled : 17:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.09%
H: 0.27%
C: -0.13%
yescarta t-cell treatment care therapy
Global HIV Treatment Market Report 2023: Advances in Gene Therapy Present Significant Opportunities for Sector Growth
Published: 2023-05-31 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $19.54 -14.18% 2.6K
|
Health Technology
|
| O: -0.24%
H: 2.1%
C: 2.1%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.0%
H: 0.66%
C: 0.33%
TEVA | $13.01 -0.68% 7.5M
|
Health Technology
|
| O: 0.42%
H: 0.83%
C: -0.41%
JNJ | News | $148.53 -0.69% -0.14% 9.6M
|
Health Technology
|
| O: -0.34%
H: 0.32%
C: 0.0%
GSK | News | $40.86 -0.92% -0.15% 1.7M
|
Health Technology
|
| O: -0.24%
H: 1.43%
C: 0.84%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.03%
H: 0.41%
C: 0.34%
ABBV | News | $167.8 -1.03% -0.06% 4.1M
|
Health Technology
|
| O: -1.96%
H: 0.0%
C: -1.35%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: -0.09%
H: 0.97%
C: 0.89%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.78%
H: 0.0%
C: -1.72%
report treatment global hiv therapy growth market
CHMP Adopts Positive Opinion Recommending Hepcludex® (Bulevirtide) for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus (HDV)
Published: 2023-05-04 (Crawled : 12:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.2%
H: 0.09%
C: -1.37%
hepcludex hepatitis chmp authorization positive treatment virus
Kite’s Yescarta® CAR T-cell Therapy Demonstrates a Statistically Significant Improvement in Overall Survival for Initial Treatment of Relapsed/Refractory Large B-cell Lymphoma
Published: 2023-03-21 (Crawled : 19:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.08%
H: 0.66%
C: -0.48%
yescarta t-cell treatment therapy
Sunlenca® (lenacapavir) Receives FDA Approval as a First-in-Class, Twice-Yearly Treatment Option for People Living With Multi-Drug Resistant HIV
Published: 2022-12-22 (Crawled : 18:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.03%
H: 0.26%
C: 0.04%
sunlenca treatment fda hiv approval living
Pediatric Health Market Research Report by Type, Therapeutics, Treatment, Treatment Type, Region - Global Forecast to 2027 - Cumulative Impact of COVID-19
Published: 2022-11-03 (Crawled : 19:00) - prnewswire.com
SNYNF | News | $94.25 -2.18% 480
|
Health Technology
|
| O: -0.02%
H: 0.43%
C: 0.43%
AZNCF | News | $140.3 -4.19% 1.5K
|
Health Technology
|
| O: -1.02%
H: 2.67%
C: 0.18%
NVSEF | News | $96.0 6.88% 52K
|
Health Technology
|
| O: 2.28%
H: 0.0%
C: 0.0%
VTRS | News A | $11.55 1.67% 1.65% 7.2M
|
Health Technology
|
| O: 0.83%
H: 1.33%
C: -0.51%
NVS | News | $98.35 1.1% 0.0% 2.2M
|
Health Technology
|
| O: 1.13%
H: 0.63%
C: 0.53%
LLY | News | $732.2 -1.81% 0.18% 2.1M
|
Health Technology
|
| O: 0.97%
H: 0.18%
C: -2.13%
BMY | $48.86 -0.27% -0.02% 16M
|
Health Technology
|
| O: 0.42%
H: 0.59%
C: -0.04%
ABT | News | $106.89 -0.65% -0.22% 5.1M
|
Health Technology
|
| O: 1.43%
H: 0.41%
C: 0.25%
SNY | News | $46.66 -2.16% -2.21% 1.7M
|
Health Technology
|
| O: 2.05%
H: 0.0%
C: 0.0%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.4%
H: 2.75%
C: 1.52%
AZN | News | $71.175 0.46% 0.46% 6.1M
|
Health Technology
|
| O: 0.72%
H: 1.29%
C: 1.04%
covid-19 treatment research global report impact health market
U.S. Food and Drug Administration Approves Vemlidy® (tenofovir alafenamide) for Treatment of Chronic Hepatitis B Virus Infection in Pediatric Patients
Published: 2022-11-02 (Crawled : 12:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -1.46%
H: 2.33%
C: -0.38%
vemlidy treatment hepatitis drug virus food infection chronic hepatitis b
Gilead to Present Data Across Viral Hepatitis and Liver Fibrosis at The Liver Meeting® 2022, Reinforcing Gilead as a Leader in Addressing Treatment Needs for People Living With Liver Disease
Published: 2022-11-01 (Crawled : 16:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.25%
H: 1.65%
C: 1.38%
meeting treatment hepatitis fibrosis liver disease living
Gilead Presents Real-World Evidence Reinforcing the Use of Biktarvy® for the Treatment of People Living With HIV With a Range of Comorbidities
Published: 2022-10-24 (Crawled : 08:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.47%
H: 1.85%
C: 1.31%
biktarvy treatment hiv living
Global Cervical Cancer Treatment Market Size Expected to Reach $11 Billion By 2027
Published: 2022-10-06 (Crawled : 13:00) - prnewswire.com
ZLAB | $15.66 3.57% 3.45% 430K
|
Health Technology
|
| O: 0.35%
H: 1.48%
C: -4.65%
SGEN | $228.74 0.1% 20M
|
Health Technology
|
| O: 0.04%
H: 0.67%
C: -0.47%
PDSB | $3.26 1.88% 1.84% 450K
|
Health Technology
|
| O: -0.55%
H: 6.11%
C: -0.56%
ILMN | $122.74 -1.38% -1.4% 1.2M
|
Health Technology
|
| O: -0.88%
H: 1.39%
C: -1.79%
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.86%
H: 0.72%
C: 0.09%
treatment global expected cancer market
CHMP Adopts Positive Opinion to Extend Indication of Veklury® (Remdesivir) for the Treatment of Pediatric Patients with COVID-19
Published: 2022-09-16 (Crawled : 11:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: 0.12%
H: 1.31%
C: 0.8%
covid-19 veklury treatment chmp positive
Gilead Announces First Global Regulatory Approval of Sunlenca® (Lenacapavir), the Only Twice-Yearly HIV Treatment Option
Published: 2022-08-22 (Crawled : 10:00) - biospace.com/
GILD | $67.07 0.06% 0.06% 8.3M
|
Health Technology
|
| O: -0.2%
H: 0.06%
C: -1.3%
sunlenca treatment global hiv approval
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.